Clinical and laboratory features of patients with acquired hemophilia
Case no. . | Age, y . | Sex . | Clinical presentation . | Associated conditions . | Disease duration . | Previous therapies . | LAC . | ANA . | FVIII activity . | FVIII inhibited titers, BU . |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 70 | F | GI bleeding, muscular hematomas, ecchymoses | Rheumatoid arthritis | 1 d | None | + | + | < 1% | 160 |
| 2 | 74 | M | Ecchymoses, prolonged bleeding after cuts | Low-grade NHL | 2 wk | None | − | − | < 1% | 4 |
| 3 | 61 | M | Muscular hematomas, epistaxis | None | 3 mo | PDN, CTX | − | − | < 1% | 28 |
| 4 | 49 | M | Ecchymoses, hematuria | None | 1 wk | None | − | − | < 1% | 32 |
| 5 | 30 | F | Ecchymoses | After pregnancy | 2 mo | None | − | − | < 1% | 16 |
| 6 | 27 | F | Epistaxis, prolonged bleeding after cuts | None | 10 d | None | + | + | < 1% | 96 |
| 7 | 78 | M | Ecchymoses, gingival bleeding | Prostate carcinoma | 3 mo | PDN, CTX | − | − | < 1% | 64 |
| 8 | 62 | F | Ecchymoses, muscular hematomas, gingival bleeding, hemarthroses | None | 13 mo | PDN, CVP, CTX, PE, rFVIIa | − | − | < 1% | 250 |
| 9 | 58 | F | Ecchymoses, menorrhagia | None | 5 d | None | + | − | < 1% | 96 |
| 10 | 68 | M | Ecchymoses, epistaxis | None | 6 mo | PDN, CTX | − | − | < 1% | 16 |
Case no. . | Age, y . | Sex . | Clinical presentation . | Associated conditions . | Disease duration . | Previous therapies . | LAC . | ANA . | FVIII activity . | FVIII inhibited titers, BU . |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 70 | F | GI bleeding, muscular hematomas, ecchymoses | Rheumatoid arthritis | 1 d | None | + | + | < 1% | 160 |
| 2 | 74 | M | Ecchymoses, prolonged bleeding after cuts | Low-grade NHL | 2 wk | None | − | − | < 1% | 4 |
| 3 | 61 | M | Muscular hematomas, epistaxis | None | 3 mo | PDN, CTX | − | − | < 1% | 28 |
| 4 | 49 | M | Ecchymoses, hematuria | None | 1 wk | None | − | − | < 1% | 32 |
| 5 | 30 | F | Ecchymoses | After pregnancy | 2 mo | None | − | − | < 1% | 16 |
| 6 | 27 | F | Epistaxis, prolonged bleeding after cuts | None | 10 d | None | + | + | < 1% | 96 |
| 7 | 78 | M | Ecchymoses, gingival bleeding | Prostate carcinoma | 3 mo | PDN, CTX | − | − | < 1% | 64 |
| 8 | 62 | F | Ecchymoses, muscular hematomas, gingival bleeding, hemarthroses | None | 13 mo | PDN, CVP, CTX, PE, rFVIIa | − | − | < 1% | 250 |
| 9 | 58 | F | Ecchymoses, menorrhagia | None | 5 d | None | + | − | < 1% | 96 |
| 10 | 68 | M | Ecchymoses, epistaxis | None | 6 mo | PDN, CTX | − | − | < 1% | 16 |
LAC indicates lupus anticoagulant; ANA, antinuclear antibodies; GI, gastrointestinal; NHL, non-Hodgkin lymphoma; PDN, prednisone; CTX, cyclophosphamide; CVP, cyclophosphamide, vincristine, prednisone; PE, plasma exchange; rFVIIa, recombinant human activated factor VII.